Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)Yannis Metaxas, Roger von Moos, E.I. Eboulet et al.|Annals of Oncology|2020Cited by 32